Agomelatine reversal of escitalopram-induced apathy: A case report

Psychiatry and Clinical Neurosciences

Volumn 67, Issue 3, 2013, Pages 190-191

  De Berardis, Domenico ^a,b   Valchera, Alessandro ^c   Fornaro, Michele ^d   Serroni, Nicola ^a   Marini, Stefano ^a,b   Moschetta, Francesco Saverio ^a   Martinotti, Giovanni ^b   Di Giannantonio, Massimo ^b  

^a G Mazzini Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Hermanas Hospitalarias   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ESCITALOPRAM;

AGED; APATHY; BEDTIME DOSAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; DRIVE; HUMAN; LETTER; MAJOR DEPRESSION; MALE; MOTIVATION; NEUROIMAGING; RECURRENT DISEASE; SIDE EFFECT; SYMPTOMATOLOGY;

ACETAMIDES; AGED; APATHY; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MOTIVATION; NEUROPSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84876234301     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12032     Document Type: Letter

References (4)

1. Sansone RA, Sansone LA,. SSRI-induced indifference. Psychiatry 2010; 7: 14-18.
2. Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH,. Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann. Pharmacother. 2012; 46: e8.
3. De Berardis D, Di Iorio G, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine. CNS Neurol. Disord. Drug Targets 2011; 10: 119-132.
4. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A,. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin. Investig. Drugs 2012; 21: 1503-1522.